All the news articles and press releases in one place.

Search
Date / Time Source Ticker Company Sector Market Cap Announcement
02Dec22 11:15 RNS SAN:PAR, 0A2V:LON Sanofi, Sanofi Sponsored ADR Various Various Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13 RNS SAN:PAR, 0A2V:LON Sanofi, Sanofi Sponsored ADR Various Various Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56 GNW 0O59:LON Sanofi Health 0m Annual General Meeting of April 30, 2021
28Apr21 06:30 GNW 0O59:LON Sanofi Health 0m Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00 GNW 0O59:LON Sanofi Health 0m Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05 GNW 0O59:LON Sanofi Health 0m New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00 GNW 0O59:LON Sanofi Health 0m European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45 GNW 0O59:LON Sanofi Health 0m Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01 GNW 0O59:LON Sanofi Health 0m Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03 GNW 0O59:LON Sanofi Health 0m Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15 GNW 0O59:LON Sanofi Health 0m FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05 GNW 0O59:LON Sanofi Health 0m Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30 GNW 0O59:LON Sanofi Health 0m Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00 GNW 0O59:LON Sanofi Health 0m Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
12Mar21 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18 GNW 0O59:LON Sanofi Health 0m Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00 GNW 0O59:LON Sanofi Health 0m FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00 GNW 0O59:LON Sanofi Health 0m Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00 GNW 0O59:LON Sanofi Health 0m FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40 GNW 0O59:LON Sanofi Health 0m Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00 GNW 0O59:LON Sanofi Health 0m The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15 GNW 0O59:LON Sanofi Health 0m FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30 GNW 0O59:LON Sanofi Health 0m Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30 GNW 0O59:LON Sanofi Health 0m Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30 GNW 0O59:LON Sanofi Health 0m SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30 GNW 0O59:LON Sanofi Health 0m Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30 GNW 0O59:LON Sanofi Health 0m Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30 GNW 0O59:LON Sanofi Health 0m CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00 GNW 0O59:LON Sanofi Health 0m Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00 GNW 0O59:LON Sanofi Health 0m European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12 GNW 0O59:LON Sanofi Health 0m European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15 GNW 0O59:LON Sanofi Health 0m Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00 GNW 0O59:LON Sanofi Health 0m FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00 GNW 0O59:LON Sanofi Health 0m FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15 GNW 0O59:LON Sanofi Health 0m Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50 GNW 0O59:LON Sanofi Health 0m European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30 GNW 0O59:LON Sanofi Health 0m Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00 GNW 0O59:LON Sanofi Health 0m Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00 GNW 0O59:LON Sanofi Health 0m CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00 GNW 0O59:LON Sanofi Health 0m Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00 GNW 0O59:LON Sanofi Health 0m Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00 GNW 0O59:LON Sanofi Health 0m EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30 GNW 0O59:LON Sanofi Health 0m Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30 GNW 0O59:LON Sanofi Health 0m Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30 GNW 0O59:LON Sanofi Health 0m Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00 GNW 0O59:LON Sanofi Health 0m Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25 GNW 0O59:LON Sanofi Health 0m Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25 GNW 0O59:LON Sanofi Health 0m Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05 GNW 0O59:LON Sanofi Health 0m Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
18Sep20 06:00 GNW 0O59:LON Sanofi Health 0m Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00 GNW 0O59:LON Sanofi Health 0m FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00 GNW 0O59:LON Sanofi Health 0m New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00 GNW 0O59:LON Sanofi Health 0m Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00 GNW 0O59:LON Sanofi Health 0m Sanofi to acquire Principia Biopharma
Date / Time Source Company % Chg
02Dec22 11:15 RNS Sanofi, Sanofi Sponsored ADR 0.00%
Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13 RNS Sanofi, Sanofi Sponsored ADR 0.00%
Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00 GNW Sanofi 0.00%
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56 GNW Sanofi 0.00%
Annual General Meeting of April 30, 2021
28Apr21 06:30 GNW Sanofi 0.00%
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00 GNW Sanofi 0.00%
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05 GNW Sanofi 0.00%
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00 GNW Sanofi 0.00%
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00 GNW Sanofi 0.00%
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45 GNW Sanofi 0.00%
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01 GNW Sanofi 0.00%
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03 GNW Sanofi 0.00%
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15 GNW Sanofi 0.00%
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05 GNW Sanofi 0.00%
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30 GNW Sanofi 0.00%
Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00 GNW Sanofi 0.00%
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
12Mar21 06:00 GNW Sanofi 0.00%
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18 GNW Sanofi 0.00%
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00 GNW Sanofi 0.00%
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00 GNW Sanofi 0.00%
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00 GNW Sanofi 0.00%
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40 GNW Sanofi 0.00%
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00 GNW Sanofi 0.00%
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15 GNW Sanofi 0.00%
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30 GNW Sanofi 0.00%
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30 GNW Sanofi 0.00%
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30 GNW Sanofi 0.00%
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30 GNW Sanofi 0.00%
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30 GNW Sanofi 0.00%
Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00 GNW Sanofi 0.00%
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30 GNW Sanofi 0.00%
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00 GNW Sanofi 0.00%
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00 GNW Sanofi 0.00%
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00 GNW Sanofi 0.00%
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00 GNW Sanofi 0.00%
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12 GNW Sanofi 0.00%
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15 GNW Sanofi 0.00%
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00 GNW Sanofi 0.00%
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00 GNW Sanofi 0.00%
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15 GNW Sanofi 0.00%
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50 GNW Sanofi 0.00%
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30 GNW Sanofi 0.00%
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00 GNW Sanofi 0.00%
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00 GNW Sanofi 0.00%
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00 GNW Sanofi 0.00%
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00 GNW Sanofi 0.00%
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00 GNW Sanofi 0.00%
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00 GNW Sanofi 0.00%
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00 GNW Sanofi 0.00%
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30 GNW Sanofi 0.00%
Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30 GNW Sanofi 0.00%
Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30 GNW Sanofi 0.00%
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00 GNW Sanofi 0.00%
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25 GNW Sanofi 0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25 GNW Sanofi 0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05 GNW Sanofi 0.00%
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
18Sep20 06:00 GNW Sanofi 0.00%
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00 GNW Sanofi 0.00%
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00 GNW Sanofi 0.00%
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00 GNW Sanofi 0.00%
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00 GNW Sanofi 0.00%
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00 GNW Sanofi 0.00%
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00 GNW Sanofi 0.00%
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00 GNW Sanofi 0.00%
Sanofi to acquire Principia Biopharma
Date / Time Company % Chg
02Dec22 11:15 0A2V LSE,SNY NASDAQ-NMS,SAN EuronextParis,O.003562064 ORBISID,O.050247077 ORBISID,O.372678613 ORBISID 0.00%
Citigroup Global Mkt - Form 38.5(a) (EPTRI) -Sanofi
02Dec22 11:13 0A2V LSE,SNY NASDAQ-NMS,SAN EuronextParis,O.003562064 ORBISID,O.000754667 ORBISID,O.372678613 ORBISID 0.00%
Citigroup Glbl Mkt E - Form 38.5 (b) (EPT/NON-RI)
06May21 06:00 Sanofi 0.00%
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30Apr21 16:56 Sanofi 0.00%
Annual General Meeting of April 30, 2021
28Apr21 06:30 Sanofi 0.00%
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26Apr21 07:00 Sanofi 0.00%
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23Apr21 15:05 Sanofi 0.00%
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19Apr21 06:00 Sanofi 0.00%
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12Apr21 06:00 Sanofi 0.00%
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09Apr21 18:45 Sanofi 0.00%
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
09Apr21 05:01 Sanofi 0.00%
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07Apr21 08:03 Sanofi 0.00%
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31Mar21 22:15 Sanofi 0.00%
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31Mar21 15:05 Sanofi 0.00%
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19Mar21 06:30 Sanofi 0.00%
Availability of the Q1 2021 Memorandum for modelling purposes
15Mar21 06:00 Sanofi 0.00%
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
12Mar21 06:00 Sanofi 0.00%
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04Mar21 17:18 Sanofi 0.00%
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04Mar21 06:00 Sanofi 0.00%
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03Mar21 17:00 Sanofi 0.00%
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22Feb21 18:00 Sanofi 0.00%
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22Feb21 10:40 Sanofi 0.00%
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12Feb21 06:00 Sanofi 0.00%
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09Feb21 22:15 Sanofi 0.00%
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05Feb21 06:30 Sanofi 0.00%
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
05Feb21 06:30 Sanofi 0.00%
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12Jan21 13:30 Sanofi 0.00%
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11Jan21 07:30 Sanofi 0.00%
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17Dec20 21:30 Sanofi 0.00%
Availability of the Q4 2020 Memorandum for modelling purposes
15Dec20 06:00 Sanofi 0.00%
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11Dec20 13:30 Sanofi 0.00%
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
11Dec20 06:00 Sanofi 0.00%
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09Dec20 06:00 Sanofi 0.00%
Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30Nov20 06:00 Sanofi 0.00%
Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23Nov20 09:00 Sanofi 0.00%
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18Nov20 18:12 Sanofi 0.00%
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18Nov20 06:15 Sanofi 0.00%
Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
18Nov20 06:00 Sanofi 0.00%
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14Nov20 00:00 Sanofi 0.00%
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02Nov20 06:15 Sanofi 0.00%
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29Oct20 13:50 Sanofi 0.00%
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
29Oct20 06:30 Sanofi 0.00%
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
29Oct20 06:00 Sanofi 0.00%
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28Oct20 06:00 Sanofi 0.00%
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26Oct20 12:00 Sanofi 0.00%
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16Oct20 13:00 Sanofi 0.00%
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15Oct20 13:00 Sanofi 0.00%
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13Oct20 06:00 Sanofi 0.00%
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02Oct20 06:00 Sanofi 0.00%
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28Sep20 14:30 Sanofi 0.00%
Sanofi completes Principia Biopharma Inc. acquisition
25Sep20 06:30 Sanofi 0.00%
Availability of the Q3 2020 Memorandum for modelling purposes
22Sep20 17:30 Sanofi 0.00%
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
22Sep20 06:00 Sanofi 0.00%
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21Sep20 13:25 Sanofi 0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
21Sep20 01:25 Sanofi 0.00%
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18Sep20 08:05 Sanofi 0.00%
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
18Sep20 06:00 Sanofi 0.00%
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14Sep20 06:00 Sanofi 0.00%
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10Sep20 06:00 Sanofi 0.00%
New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08Sep20 06:00 Sanofi 0.00%
Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03Sep20 06:00 Sanofi 0.00%
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01Sep20 06:00 Sanofi 0.00%
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28Aug20 06:00 Sanofi 0.00%
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17Aug20 06:00 Sanofi 0.00%
Sanofi to acquire Principia Biopharma